Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$16.78 -2.26%

-$0.42 today

Market cap
$1.98B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 1.41M

Average 1.23M

IMNM Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Immunome, Inc.NASDAQ: IMNM

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation growth accelerates

Q3 FY2026 stock-based compensation of $12.76M rose 89.1% year over year, ahead of the +60.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 45.0% from the prior quarter. Over 3 fiscal years it compounded at +68.9% a year.

Context

  • Stock-based compensation amounted to 370.1% of revenue in FY2025, up 195.9 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +89.1% holds above the trailing-twelve-month pace of +60.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$12.76M+45.0% QoQ
Last fiscal yearDec 2025
$25.69M+63.1% YoY
LTMSep 2026
$37.41M+60.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+89.1%——
1 year+63.1%——
3-year CAGR+68.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
25.69M USD
Year-over-year change
+63.1%
4-year CAGR
+65.2%

Stock-Based Compensation vs competitors

How IMNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +60.8% is the 4th highest of 11, against a peer median of -13.9%.
  • Over three fiscal years its annual growth of +68.9% compares with a peer median of +13.8%.
IMNM Competitors
Stock-Based Compensation for IMNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMNMImmunome, Inc.LTM Sep 2026$37.41M USD+60.8%+68.9%—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$36.81M USD-0.7%—32869.6%
IMCRImmunocore Holdings plcLTM Mar 2026$28.21M USD+14.1%—7.3%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$15.73M USD+224.1%+209.1%—
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M USD-55.6%-11.3%8.0%
STROSutro Biopharma, Inc.LTM Mar 2026$10.03M USD-58.5%-18.9%10.1%
IMTXImmatics N.V.LTM Mar 2026€7.38M EUR-44.8%—19.8%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$6.73M USD+88.8%+25.6%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$4.19M USD+122.7%+4.3%—
BCYCBicycle Therapeutics plcLTM Mar 2026$2.68M USD-107.0%+13.8%4.2%
IMMXImmix Biopharma, Inc.LTM Mar 2026$2.15M USD-27.0%+57.6%—
Peer median (excluding IMNM) —-13.9%+13.8%9.0%

Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Depreciation & Amortization755K631K728K2.1M2.96M
Deferred Income Tax(500K)(7.27M)000
Stock-Based Compensation3.45M5.33M6.22M15.75M25.69M
Change in Working Capital2.78M2.24M12M14.87M(15.23M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.78M(677K)(608K)9.53M(9.16M)
Other Working Capital998K2.92M12.61M5.35M(6.06M)
Other Non-Cash Items4K7.27M80.29M149.45M8.06M
Operating Cash Flow(18.23M)(28.69M)(7.57M)(110.79M)(190.92M)
Capital Expenditures(79K)(248K)(831K)(53.51M)(9.69M)
Acquisitions (Net)009.28M00
Purchases of Investments00(38.93M)(186.56M)(123.27M)
Sales of Investments000155M200M
Other Investing Activities000(46.34M)(6.25M)
Investing Cash Flow(79K)(248K)(30.48M)(85.06M)60.8M
Debt Repayment(113K)0000
Common Stock Issued27.23M32K34K250M640.36M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities656K0116.37M(9.47M)0
Financing Cash Flow27.77M32K116.41M240.53M640.36M
Effect of Forex Changes00000
Net Change in Cash9.46M(28.91M)78.36M44.67M510.24M
Free Cash Flow(18.31M)(28.94M)(8.4M)(164.3M)(200.6M)

Immunome, Inc.

NASDAQ:IMNM

Intrinsic Alpha fair value

Locked

Current Price

$16.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.